Skip to main content

CRBU

Stock

CRBU

Stock
Health Care
Biotechnology

Performance overview

CRBU Price
Price Chart

Forward-looking statistics

Beta
1.17
Risk
76.86%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees135
Market cap$176.1M

Fundamentals

Enterprise value-$65.1M
Revenue$9.9M
Revenue per employee
Profit margin0.00%
Debt to equity12.07

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.62
Dividend per share
Revenue per share$0.11
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$4M
Put-call ratio

Macro factor sensitivity

Growth-3.3
Credit+10.2
Liquidity-1.3
Inflation-7.2
Commodities-1.3
Interest Rates-2.4

Valuation

Dividend yield0.00%
PEG Ratio-0.69
Price to sales12.85
P/E Ratio-0.69
Enterprise Value to Revenue-6.56
Price to book0.59

Upcoming events

Next earnings dayMarch 12, 2024
Next dividend day
Ex. dividend day

News

Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know

Caribou Biosciences (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (May 13, 2025)
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability

Caribou Biosciences Inc (NASDAQ: CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).  Following a single dose at the initial dose level of 40 million CAR.

Benzinga (June 13, 2022)
Caribou CEO discusses his company's unicorn status, its plans going forward, and its culture

Caribou CEO Kevin Bennett sits down with Yahoo Finance Live to discuss his company's business outlook after receiving funding, car price trends, and refinancing cars.

Yahoo Finance (May 19, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free